Evaluation of four immunoassay screening kits for the detection of benzodiazepines in urine

被引:18
作者
DeRienz, Rebecca T. [1 ]
Holler, Justin A. [1 ]
Manos, Megan E. [1 ]
Jemionek, John [1 ]
Past, Marilyn R. [1 ]
机构
[1] Armed Forces Inst Pathol, Armed Forces Med Examiner Syst, Div Forens Toxicol, Rockville, MD 20850 USA
关键词
D O I
10.1093/jat/32.6.433
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The identification of benzodiazepines (BZD) in biological fluids can be a challenging process. The large number of various BZD in pharmaceutical distribution, with similar core structures, and individual metabolic profiles all contribute to a complicated and time-consuming analysis. The purpose of the current study was to evaluate the performance of four commercially available immunoassay urine screening kits for use in a forensic urine analysis testing program. The four kits included the Roche Benzodiazepine Plus KIMS assay, Microgenics CEDIA® Benzodiazepine assay, Microgenics CEDIA high sensitivity assay with β-glucuronidase, and Microgenics DRI® reagent ready Benzodiazepine assay. Each kit was evaluated for linearity, precision, accuracy, carryover, reagent specificity, and confirmation rates. BZD reagent specificity was compared by analysis of 55 structurally dissimilar compounds to BZD. Negative responses to all 55 compounds were elicited by all four reagent assays. Cross-reactivity for the assays was demonstrated by detecting 27 structurally similar BZD. In addition, greater than 10,000 randomly collected urine samples were screened at a 200 ng/mL cutoff for each assay. Positive samples were confirmed by gas chromatography-mass spectrometry using a panel of 13 BZD confirmation standards. The Microgenics CEDIA high sensitivity assay demonstrated the highest positive screening rate as well as the highest confirmation rate of the four assays.
引用
收藏
页码:433 / 437
页数:5
相关论文
共 17 条
[1]  
Baselt RC., 2004, Disposition of Toxic Drugs and Chemicals in Man, V7th
[2]  
Brunton L, 2006, GOODMAN GILMANS PHAR, P401
[3]   METABOLISM OF LORAZEPAM [J].
ELLIOTT, HW .
BRITISH JOURNAL OF ANAESTHESIA, 1976, 48 (10) :1017-1023
[4]   Use and abuse of the benzodiazepines [J].
Fraser, AD .
THERAPEUTIC DRUG MONITORING, 1998, 20 (05) :481-489
[5]   IMMUNOASSAY DETECTION OF BENZODIAZEPINES AND BENZODIAZEPINE METABOLITES IN BLOOD [J].
HUANG, W ;
MOODY, DE .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1995, 19 (06) :333-342
[6]   The behavioural and neuronal effects of the chronic administration of benzodiazepine anxiolytic and hypnotic drugs [J].
Hutchinson, MA ;
Smith, PF ;
Darlington, CL .
PROGRESS IN NEUROBIOLOGY, 1996, 49 (01) :73-97
[7]  
Katzung B.G., 2001, BASIC CLIN PHARMACOL, V8th, P364
[8]   Urine benzodiazepine screening using Roche Online® KIMS immunoassay with β-glucuronidase hydrolysis and confirmation by gas chromatography-mass spectrometry [J].
Klette, KL ;
Wiegand, RF ;
Horn, CK ;
Stout, PR ;
Magluilo, J .
JOURNAL OF ANALYTICAL TOXICOLOGY, 2005, 29 (03) :193-200
[9]  
KNOWLES JA, 1972, ARZNEI-FORSCHUNG, V22, P687
[10]   IMPROVED SCREENING FOR BENZODIAZEPINE METABOLITES IN URINE USING THE TRIAGE(TM) PANEL FOR DRUGS OF ABUSE [J].
KOCH, TR ;
RAGLIN, RL ;
KIRK, S ;
BRUNI, JF .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1994, 18 (03) :168-172